News | November 14, 2024
AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
He specializes in financial planning, audit, compliance and ERP implementation, with extensive experience in leading automation and risk management projects
Construction of the plant will commence in 2025 with first production expected to be in 2027
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Subscribe To Our Newsletter & Stay Updated
